UK's Syncona gains after Beacon gene therapy trial meets endpoint

By Reuters News

** Shares of British healthcare investment firm Syncona SYNCS.L up 6% at 118 pence

** Co says portfolio company Beacon Therapeutics' Phase II/III VISTA trial meets FDA-endorsed primary endpoint for gene therapy laru-zova

** Response rate was 31% in the high-dose arm and 24.1% in the low-dose arm

** Data supports Beacon's plans to begin regulatory discussions and start a rolling US biologics licence application submission later in 2026

** YTD, stock is up ~24%

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk